Miniaturized screening technologies for drug discovery

2002 ◽  
Vol 30 (4) ◽  
pp. 802-806 ◽  
Author(s):  
J. M. Cooper ◽  
A. E. G. Cass
Keyword(s):  
Drug Discovery ◽  
Molecular Biology ◽  
Pharmaceutical Research ◽  
Toxicity Assessment ◽  
Clinical Development ◽  
Biological Screening ◽  
Drug Candidates ◽  
The Us ◽  
Pharmaceutical Research And Development ◽  
Microsystems Technology

Adaptive Profiling (APL) and other biochip companies aim to harness the power of microsystems technology together with advances in chemistry and molecular biology, to become service and technology providers to organizations involved in pharmaceutical research and development. By supplying a unique range of decisionmaking tools that aid an earlier identification of qualified drug candidates for clinical development, the company should gain a significant share of the US$10 billion biological screening, bioavailability and toxicity assessment market.

scholarly journals Conference 2016: From Drug Discovery to Health Outcomes: Population to Patient. An international symposium held jointly by CSPS and CC-CRS, May 31-June 3, 2016, Vancouver, BC, Canada

2016 ◽  
Vol 19 (3) ◽  
pp. 1
Author(s):  
Beverley Berekoff
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Research ◽  
Lessons Learned ◽  
Knowledge Generation ◽  
Pharmaceutical Sciences ◽  
University Of Alberta ◽  
University Of Toronto ◽  
Lifetime Achievement ◽  
Life Sciences Industry ◽  
Pharmaceutical Research And Development

Plenaries and Special Presentations:Carolyn Buser-Doepner, GSK:  "New Trends in Pharma-Academia Collaborations for Drug Discovery"Chris Halyk, President, Janssen Inc.:  "Are Innovative Medicines and our Life Sciences Industry at Risk in Canada?"Aaron Schimmer, Princess Margaret Cancer Centre:  "New Therapeutic Strategies to Target the Mitochondria in Leukemia"Ivana Cecic, Genome BC:  "Genomics in Canada: From Knowledge Generation to Patient Outcomes"Adam Rosebrock, University of Toronto:  "Quantitative Mass-Spectrometry Metabolomics for Direct Biochemical Phenotyping"Fakhreddin Jamali, University of Alberta: CSPS Lifetime Achievement Award Lecture - "Pharmaceutical Research and Development, Lessons Learned"Conference Sessions:Special Session: Innovation and Management of Modern Pharmaceuticals1. Special Populations2. Nanomedicines Become Personal: Opportunities and Challenges3. Mucosal Drug Delivery4. Broaching the Fourth Hurdle: Getting Drugs on the Formulary5. Pharmacogenomics in the Clinic and Community6. Responsive Drug Delivery Systems7. Drug Targeting and Targeting Drugs8. Health Sustainability Evidence9. Integrating Pharmaceutical Sciences into a Pharm D Curriculum10. Analytical Innovation to Support Precision Medicine and Biologicals Development11. Protein and Peptide Delivery

scholarly journals Development and Application of an Automated Solution Stability Assay for Drug Discovery

2005 ◽  
Vol 11 (1) ◽  
pp. 40-47 ◽  
Author(s):  
Li Di ◽  
Edward H. Kerns ◽  
Hong Chen ◽  
Susan L. Petusky
Keyword(s):  
Drug Discovery ◽  
High Performance ◽  
Time Course ◽  
Pharmaceutical Research ◽  
Forced Degradation ◽  
Solution Stability ◽  
Ph Profile ◽  
Drug Candidates ◽  
The Stability ◽  
Excipient Compatibility

Screening of solution stability provides an early alert on potential liabilities of drug candidates so that strategies can be developed to overcome the challenges. Afully automated solution stability assay has been developed to accelerate traditionalmanual operation. The assay uses the advanced capabilities of a high-performance liquid chromatography instrument that is present in many pharmaceutical research laboratories. The samples are prepared automatically by a temperature-controlled autosampler. The samples are delivered to the stability matrices, mixed, incubated, and injected at selected time points during the reaction time course. This automated process occurs without operator intervention, thus allowing 96 experiments to be run with0.5hof a scientist's time compared to 8 h for the same studywhenperformedmanually. Automationnotonly eliminates themanual operation but also improves accuracy and throughput. The assay protocol has been optimized to achieve homogenous mixing and eliminate carryover. The assay is robust, flexible, and high throughput. It can be used to study stability for a large number of samples undermultiple incubation conditions and has awide range of applications in drug discovery and development, such as screening compound stability in biological assaymedia, obtaining a stability-pH profile, surveying compound stability in physiological fluids, and performing development forced degradation and excipient compatibility.

Application of Advanced Technologies in Natural Product Research: A Review with Special Emphasis on ADMET Profiling

2020 ◽  
Vol 21 (10) ◽  
pp. 751-767
Author(s):  
Pobitra Borah ◽  
Sangeeta Hazarika ◽  
Satyendra Deka ◽  
Katharigatta N. Venugopala ◽  
Anroop B. Nair ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Natural Product ◽  
Dynamic Range ◽  
Early Stage ◽  
Attrition Rate ◽  
Drug Candidates ◽  
Advanced Technologies ◽  
Natural Product Research ◽  
The Status ◽  
Safety Parameters

The successful conversion of natural products (NPs) into lead compounds and novel pharmacophores has emboldened the researchers to harness the drug discovery process with a lot more enthusiasm. However, forfeit of bioactive NPs resulting from an overabundance of metabolites and their wide dynamic range have created the bottleneck in NP researches. Similarly, the existence of multidimensional challenges, including the evaluation of pharmacokinetics, pharmacodynamics, and safety parameters, has been a concerning issue. Advancement of technology has brought the evolution of traditional natural product researches into the computer-based assessment exhibiting pretentious remarks about their efficiency in drug discovery. The early attention to the quality of the NPs may reduce the attrition rate of drug candidates by parallel assessment of ADMET profiling. This article reviews the status, challenges, opportunities, and integration of advanced technologies in natural product research. Indeed, emphasis will be laid on the current and futuristic direction towards the application of newer technologies in early-stage ADMET profiling of bioactive moieties from the natural sources. It can be expected that combinatorial approaches in ADMET profiling will fortify the natural product-based drug discovery in the near future.

Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances

2019 ◽  
Vol 22 (8) ◽  
pp. 509-520
Author(s):  
Cauê B. Scarim ◽  
Chung M. Chin
Keyword(s):  
Drug Discovery ◽  
Chagas Disease ◽  
Drug Candidates ◽  
Lead Compounds ◽  
New Drug ◽  
Compound Libraries ◽  
Screening Assays ◽  
Cruzi Infection

Background: In recent years, there has been an improvement in the in vitro and in vivo methodology for the screening of anti-chagasic compounds. Millions of compounds can now have their activity evaluated (in large compound libraries) by means of high throughput in vitro screening assays. Objective: Current approaches to drug discovery for Chagas disease. Method: This review article examines the contribution of these methodological advances in medicinal chemistry in the last four years, focusing on Trypanosoma cruzi infection, obtained from the PubMed, Web of Science, and Scopus databases. Results: Here, we have shown that the promise is increasing each year for more lead compounds for the development of a new drug against Chagas disease. Conclusion: There is increased optimism among those working with the objective to find new drug candidates for optimal treatments against Chagas disease.

Targeted Protein Degradation: "The Gold Rush is On!"

2020 ◽  
Vol 7 (1) ◽  
pp. 4-16
Author(s):  
Daria Kotlarek ◽  
Agata Pawlik ◽  
Maria Sagan ◽  
Marta Sowała ◽  
Alina Zawiślak-Architek ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Protein Degradation ◽  
Small Molecule ◽  
Gold Rush ◽  
European Company ◽  
Drug Candidates ◽  
Protein Inhibition ◽  
Small Molecule Drug ◽  
Therapeutic Benefits ◽  
Talent Pool

Targeted Protein Degradation (TPD) is an emerging new modality of drug discovery that offers unprecedented therapeutic benefits over traditional protein inhibition. Most importantly, TPD unlocks the untapped pool of the proteome that to date has been considered undruggable. Captor Therapeutics (Captor) is the fourth global, and first European, company that develops small molecule drug candidates based on the principles of targeted protein degradation. Captor is located in Basel, Switzerland and Wroclaw, Poland and exploits the best opportunities of the two sites – experience and non-dilutive European grants, and talent pool, respectively. Through over $38 M of funding, Captor has been active in three areas of TPD: molecular glues, bi-specific degraders and direct degraders, ObteronsTM.

scholarly journals Pharmacodynamic assays to facilitate preclinical and clinical development of pre‐ mRNA splicing modulatory drug candidates

2015 ◽  
Vol 3 (4) ◽  
Author(s):  
Yihui Shi ◽  
Amanda S. Joyner ◽  
William Shadrick ◽  
Gustavo Palacios ◽  
Chandraiah Lagisetti ◽  
...  
Keyword(s):  
Clinical Development ◽  
Mrna Splicing ◽  
Drug Candidates
Sign in / Sign up

Export Citation Format

Share Document